Moderna Triples Corona Vaccine Sales in First Quarter
US biotechnology company Moderna more than tripled sales of its corona vaccine in the first quarter compared to a year ago. As a result, the company’s profits were three times higher than in the first quarter of 2021.
Moderna achieved a turnover of 5.9 billion dollars last quarter with its corona vaccine, beating analysts’ expectations. When the vaccine first came on the market, sales were $1.7 billion a year ago. Total sales amounted to $6.1 billion. Net profit rose to $3.7 billion from $1.2 billion a year ago.
The company maintained its expectation to realize a turnover of at least $ 21 billion this year with its corona vaccine. This expectation is based on orders and is likely to be higher.
CEO Stéphane Bancel said he expects Moderna to sell even more vaccines in the second half as governments order more shots to prepare for the vaccination campaigns in the fall. Bancel also expects to receive approval in the late summer for the modified vaccine against the omikron variant of the coronavirus.